The information on this website is intended for healthcare professionals only and is provided for the purpose of scientific exchange.
The website is not country specific and may therefore contain information that is not applicable in your country, thus you may find information concerning study drugs or therapeutic uses that have not been approved by drug regulatory agencies. This website is not intended to promote in any way, any use, either approved, or unapproved, of a Novo Nordisk product or of any other product or serve as basis for any treatment decision or action. Please always refer to Summary of Product Characteristics (product label) as approved by regulatory authorities in your country or contact Novo Nordisk for further information.
Furthermore, the site is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. Only a physician can determine whether a specific product is correct for a particular patient. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site.
By accessing this website you accept this legal notice and expressly confirm your status as a healthcare professional.
Dr Subodh Verma is an internationally renowned cardiac
surgeon-scientist and Professor at the University of Toronto. He is
the current Canada Research Chair in Cardiovascular Surgery, having
previously served as the Canada Research Chair in Atherosclerosis
(2007-2017). Dr Verma was recently awarded the 2021 Lister Prize in
Surgery from the University of Toronto in recognition of his
outstanding and continuing productivity of international stature. He
is a past recipient of the Howard Morgan Award for Distinguished
Achievements in Cardiovascular Research and the Royal College of
Physicians and Surgeons of Canada Gold Medal in Surgery. He is an
appointee of the American Association of Thoracic Surgeons (AATS) and
a member of the College of New Scholars, Artists and Scientists, Royal
Society of Canada. According to Google Scholar in April 2021, Dr Verma
has an hindex of 100 and his work has been cited over 50,000
times.
Dr Verma has published extensively in
highly impactful journals like the NEJM, Lancet, Circulation, JACC,
Nature, and JCI. He is an Associate Editor of the European Heart
Journal. Dr Verma is an active contributor to Canadian clinical
practice guidelines and co-authored the recently updated
recommendations for atrial fibrillation, antiplatelet therapy,
diabetes, and heart failure; he was a member of the 2018 AATS
consensus guidelines committee on bicuspid aortic valve-related
aortopathy. Dr Verma has served in various capacities on the American
Heart Association Councilon Cardiovascular Surgery and Anesthesia
since 2008.
Dr Verma had/has leadership roles on
10 contemporary global heart failure trials – several of which have
let to paradigm changes in how individuals all around the world who
live with diabetes and heart failure are now managed. He founded and
oversees the CardioLink platform at St Michael’s Hospital that is
conducting cardiometabolic and surgically oriented RCTs and
translational studies.
Dr Verma leads a dynamic pre-clinical and translational research team that leverages pre-clinical disease models and clinical trial-derived data to identify novel mediators of cardiovascular and cardiometabolic disease as well as answer timely and relevant healthcare questions. His research has yielded 2 United States patents and is supported by several national peer-reviewed grants.